Notably, the use of gap junction inhibitors such as carbenoxolone (CBX), mefloquine (MQ), and 2-aminoethoxydiphenyl borate (2-APB) successfully blocked these processes, thereby preventing the spread of α-synuclein aggregates in PD and MSA models [139]. Here, SNCA is linked to Parkinson disease.